BN Business News
Add your company to Business Communicator →

Business · 14/04/1994Updated: 10/15/2026 · 1 min read

Prospective Grant of Exclusive License: Treatment of Dopaminergic Neurodegenerative Disorders

Summary

The National Institutes of Health (NIH) is contemplating granting an exclusive worldwide license to Phoenix: Regenerative Technologies, Inc. for a novel surgical implantation method to treat dopaminergic neurodegenerative disorders, pending no objections within 60 days.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →